MedTrace Logo

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

NCT00148668 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2013-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 positive breast cancer.

Conditions

Interventions

DRUG

Herceptin

One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.

DRUG

Navelbine

Weekly injections given starting week 3 and ending week 14

DRUG

Taxotere

Given every three weeks starting week 3 and ending on week 14

DRUG

Carboplatin

Given every three weeks starting week 3 and ending on week 14

Sponsors & Collaborators

Principal Investigators

  • Eric Winer, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2009-01-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148668 on ClinicalTrials.gov